Launch of biomarker assay for Alzheimer's disease
2011年8月24日 - 3:01PM
RNSニュース (英語)
TIDMNGG
NextGen Group PLC
24 August 2011
NextGen Sciences launches multiplex protein CSF biomarker assay
for Alzheimer's disease
Ann Arbor, Michigan, US and London, UK, 24 August 2011 - NextGen
Group plc (AIM:NGG) is pleased to announce that its US-subsidiary
NextGen Sciences Inc, a leader in biomarker discovery, measurement
and qualification, has launched its csfalzheimers37 multiplex
protein assay for Alzheimer's disease. The assay simultaneously
measures 37 human CSF (cerebrospinal fluid) proteins that are
believed to have potential as biomarkers for the disease.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented,
'The release of the csfalzheimers37 assay demonstrates our firm
intention to focus on the major CNS (Central Nervous System)
diseases and comes hot on the heels of the release of the
csfmultiplesclerosis25 assay for Multiple Sclerosis and
csfparkinsons22 assay for Parkinson's disease. To ensure we
continually deliver the high-quality assays that pharmaceutical,
biotechnology, diagnostics, and translational medicine
organizations need to inform their decision-making processes,
NextGen Sciences is currently working to expand its CSF and Plasma
discovery assays.'
NextGen's assay is based upon its multiple reaction monitoring
(MRM) mass spectrometry platform and generates high quality
reproducible data that companies can use in their drug and
diagnostic development programmes. The MRM platform can be used to
assay proteins and modified proteins for which there are no
antibodies and can thus circumvent the limitations of current
antibody based technologies. NextGen expects to develop further
oncology and CNS disease-focused assay panels, both as proprietary
products and with other companies, through partnerships and
collaborations.
- ENDS -
For more information:
NextGen Group
Klaus Rosenau, Chairman and CEO
klaus.rosenau@nextgensciences.com
+49 160 551 6756
Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 (0) 20 7107 8000
Notes to Public
NextGen Sciences Inc (Ann Arbor, MI, USA) is the subsidiary of
NextGen Group PLC, London, UK (AIM: NGG). It provides
pharmaceutical, biotechnology and diagnostic companies with rapid
and quantitative protein biomarker discovery, measurement and
qualification services using mass spectrometry technology. The
technology enables protein biomarker discovery and assay without
the need for antibodies which is a current limitation with other
biomarker assay technologies. With a rise in the industry focus on
personalized medicine and cost-effectiveness, biomarkers are
playing an increasingly important role in drug discovery,
development and patient access, as well as healthcare delivery. The
global market for biomarkers is expected to grow to $30bn by 2015
(BCC Research, 2011), with those for neurological disorders ($3.2bn
by 2015, BCC Research, 2010) and oncology ($5.7bn by 2014, Goliath,
2010) playing an important role. NextGen Sciences' products include
discovery of new biomarkers and targets, assay development, and
biomarker qualification. For more company and product information
please visit www.nextgensciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABLGDIGGDBGBX
Nextgen (LSE:NGG)
過去 株価チャート
から 5 2024 まで 6 2024
Nextgen (LSE:NGG)
過去 株価チャート
から 6 2023 まで 6 2024